Boston Partners’s Ortho Clinical Diagnostics Holdings OCDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
– Sell
-2,792,201
Closed -$52.3M – 747
2022
Q1
$52.3M Sell
2,792,201
-17,390
-0.6% -$313K 0.06% 230
2021
Q4
$59.7M Sell
2,809,591
-30,176
-1% -$595K 0.07% 231
2021
Q3
$53M Sell
2,839,767
-27,145
-0.9% -$547K 0.07% 246
2021
Q2
$61.3M Buy
2,866,912
+144,095
+5% +$2.93M 0.08% 238
2021
Q1
$52.8M Buy
+2,722,817
New +$48M 0.07% 247

Other funds holding OCDX

Boston Partners's OCDX Position: Q2 2022 in Review

Boston Partners sold out of Ortho Clinical Diagnostics Holdings (OCDX) in Q2 2022, closing a stake of 2,792,201 shares — an estimated $52.3M sold.

Boston Partners first reported a position in OCDX in Q1 2021 and held it in 5 quarters. The position peaked at $61.3M in Q2 2021. 1 fund tracked by Wall St. Rank holds OCDX as of Q2 2022.

  • Boston Partners reported no remaining Ortho Clinical Diagnostics Holdings position as of Q2 2022 after selling out during the quarter.
  • Boston Partners sold 2,792,201 Ortho Clinical Diagnostics Holdings shares in Q2 2022, an estimated $52.3M.
  • Boston Partners first reported a position in Ortho Clinical Diagnostics Holdings in Q1 2021 and held it in 5 quarters.
  • Boston Partners's Ortho Clinical Diagnostics Holdings position peaked at $61.3M in Q2 2021.
  • 1 fund tracked by Wall St. Rank held Ortho Clinical Diagnostics Holdings as of Q2 2022.

Based on Boston Partners's 13F filing for Q2 2022, filed 10 Aug 2022.